Epidemiologic studies demonstrate significant gender-specific differences in immune system function. Males are more prone to infection and malignancies, while females are more vulnerable to autoimmune diseases. These differences are thought to be due to the action of gonadal hormones: Estrogen increases the inflammatory response and testosterone dampens it. More specifically, estrogen stimulation induces inflammatory cytokine production including interferon g, interleukin (IL) 6, and tumor necrosis factor a, while testosterone induces IL-10, IL-4, and transforming growth factor b. More recent studies demonstrate threshold effects of estrogen stimulation on immune cell function: physiologic doses of estrogen (approximately 0.5 nmol/L) stimulate inflammatory cytokine production, but superphysiologic dosages (above 50 nmol/L) can result in decreased inflammatory cytokine production. This review reports findings concerning the impact of estrogen on CD8 þ cytotoxic T cells and the overall immune response in the tumor microenvironment. Variables examined include dosage of hormone, the diversity of immune cells involved, and the nature of the immune response in cancer. Collective review of these points may assist in future hypotheses and studies to determine sex-specific differences in immune responses that may be used as targets in disease prevention and treatment.
Introduction
Sex and sex hormone signaling are important factors in the pathogenesis and prognosis of cancer. For all cancers outside the reproductive tract, there is a 2-fold higher risk of malignancy in males compared to females. 1 This dimorphism is in part due to the effects of sex hormones on the tumor, the tumor microenvironment (TME), and the immune system.
Estrogen Receptor Signaling in Cancer
Estrogen is thought to have a protective role against cancer which is supported by the observation that cancer incidence and mortality rates increase after menopause in women not taking hormone replacement therapy (HRT). 2 In some specific cancers such as melanoma or liver cancer, it was shown that estrogen signaling has an antitumor role by enhancing antitumor immune responses. [3] [4] [5] Despite the normal and beneficial actions of physiological estrogen in women, estrogen was classified as a carcinogen after the Women's Health Initiative research program discovered that postmenopausal women treated with HRT had a significant increase in the incidence of breast cancer after at least 5 years of treatment. 6 Even if estrogen and estrogen receptor (ER) signaling is well known to be cancer promoting in ER-positive (ER þ ) breast tumors, ER expression and signaling are correlated with improved prognosis and survival in other cancers due to the design and use of drugs that can be used to target and block the ERs. The effects of estrogen are tissue-specific and depend on which ER is predominantly expressed and further which downstream signaling pathways become activated. Estrogen mediates its biological effects through 2 canonical receptors ERa and ERb, which are encoded by the ESR1 and ESR2 genes. The ERa and ERb are highly homologous (around 96%) and they bind to estrogen with similar affinities, but their downstream signaling pathways are very different and can even oppose each other. [7] [8] [9] The relative abundance of ERa versus ERb in a given cell type is very important for mediating tissue-specific estrogen responsiveness.
Breast Cancer and ER Expression
In breast cancer cells, ERa regulates various genes that play key roles in cell cycle progression and proliferation. The ERa can transcriptionally upregulate c-Myc (as early as 15 minutes after estrogen stimulation) and cyclin D1 which are necessary for the G1-to-S phase transition. 10, 11 On the other hand, ERb signaling can induce G2 cell cycle arrest and inhibit the estrogen-induced cancer cell proliferation. [12] [13] [14] Overall and as depicted in Figure 1A , in ER þ breast cancer cells, ERa and ERb downstream signaling play opposing roles on regulating cell cycle progression and cancer cell proliferation. When both receptors are coexpressed in cancer cells, the proliferative response induced by estrogen, and ERa signaling is countered by inhibition of cyclin E. 12 ERa also upregulates antiapoptotic genes including Bcl-2 and Bcl-X l in some tumor cells. 15 Paradoxically, ER signaling can also induce apoptosis depending on the estrogen concentration. High-dose estrogen therapy was used to treat breast cancer and reduce tumor size in postmenopausal women. 16 This correlates with the clinical observation concerning long-term treatment with tamoxifen, which is a selective estrogen receptor modulator (SERM). Tamoxifen, treatment of breast cancer, often leads to drug resistance and sensitizes breast cancer cells to high-dose estrogen therapy. 17, 18 In breast cancer cells, it was shown that ERb can oppose the antiapoptotic ERa signaling and cause cancer cell death. The ERb was shown to physically interact with p53 and inhibit the ERa-p53 binding which induces a p53 transcriptional block via heterochromatin assembly. 19 In summary, ERa and ERb have opposing effects on regulating apoptosis in breast cancer cells ( Figure 1A) .
Metastasis is described as the spread of cancer cells from the primary tumor to distal organs. It is one of the main causes of cancer-related deaths. 20 The ERa pathway seems not to stimulate metastasis since ER þ breast cancers are known to be less metastatic than those which are ER À . 21 The ERa signaling induces epithelium-related genes such as GATA3 and forkhead box protein A1, which promote epithelial over mesenchymal cell differentiation. 22, 23 Overexpressing ERa in ER À breast cancer cell lines induces the epithelial phenotype and reduces invasiveness, whereas knockdown of ERa in ER þ breast cancer cell lines leads to the mesenchymal phenotype and increased invasiveness. 24 Knowing all this, it cannot be concluded that estrogen acts exclusively as an oncogene or as a tumor suppressor in cancer. Estrogen effects on cancer depend on the concentration of the hormone, the ER dominantly expressed on the cell, and most importantly the cell type.
The expression of one or both ERs is recognized in many different hormone-sensitive cancers. Their presence and level of concentration correlate with clinical outcome. Depending on cell type and cellular localization, ER expression was differentially associated with disease prognosis. In breast cancer, ER expression in either the nucleus or the cytoplasm of the cell was concurrent with advanced disease. However, patients with ERa þ breast cancer have better overall survival than ER À due to increased response to therapies. 25, 26 The significance of ERb expression in breast cancer and most tumor cells remains controversial due to a large variety of splice variants, posttranslational modifications, and lack of availability of a validated antibody for detection.
ER Signaling in Lung Cancer
In lung cancer, ERa is found mainly in the cytoplasm of the cell, and it is a negative prognostic marker correlated with reduced 5-year survival, especially in the absence of ERb expression ( Figure 1C) . 27 Biopsies of patients with non-small cell lung cancer (NSCLC) were analyzed via immunohistochemistry, and it was determined that cytoplasmic ERa expression and lack of ERb expression in the nucleus are markers of patients with a more aggressive disease and decreased survival. 27 On the other hand, elevated ERb expression in the cytoplasm of the cell is also correlated with poor prognosis in NSCLC. 27, 28 It can be concluded that in NSCLC there is an opposing role of ERa and ERb in downstream nuclear signaling, indicating that they could be transcriptionally regulating opposing genes.
Estrogen Effects in Ovarian and Endometrial Cancer
In ovarian cancer, ERa expression was linked with improved overall survival of patients. 29 Similarly, in endometrial cancer better overall survival was observed when ERa and ERb were simultaneously expressed. 30, 31 Estrogen Effects in Melanoma Melanoma tumors express both ERa and ERb. It was shown that ERb expression decreases as the melanoma tumor develops. Although the mechanisms remain unclear, it is thought that ERb acts as a tumor suppressor but is downregulated as the tumor progresses. 5, 32 Estrogen can suppress the growth of human melanoma by inhibiting interleukin (IL) 8 production and subsequent chronic inflammation through ERa signaling ( Figure 1B ). 33 
Estrogen Effects on Prostate Cancer
In prostate cancer, the role of estrogen is controversial, since elevated estrogen levels were correlated with increased incidence risk of malignancy but also the opposite was suggested since increased cancer risk is observed in decreasing estrogen conditions. 34 
Estrogen's Role in Liver Cancer
Liver cancer is one of the most sex-driven cancers, and it has up to a 4:1 male to female incidence ratio worldwide. 1 Estrogen has antitumor properties in the liver. Studies using chemically induced liver tumor mouse models showed that estrogen signaling through ERa was able to inhibit IL-6 production by hepatocytes and Kupffer (liver resident macrophages) cells which reduced overall chronic inflammation of the liver. 35, 36 Estrogen also inhibits macrophage polarization, described as the ability of macrophages to dramatically shift from one functional profile to another, or the development of tumor-associated macrophages (TAMs) which is consistent with a better prognosis. 37 Overall and as depicted in Figure 1B , studies suggest that ER expression and estrogen presence in liver cancer has a positive correlation with better prognosis in both males and females.
Summary
Estrogen is a key molecule in cellular development and cell cycle regulation and therefore impacts many varieties of cancer cells directly. In most cancers, ERb expression is correlated with better prognosis and survival, and it can be concluded that ERb acts as a tumor suppressor. ERa acts as an oncogene in breast and lung cancers, even if ERa expression is correlated with better prognosis on melanoma, ovarian, and endometrial cancer.
Estrogen in the TME
In addition to tumor cells, ERs and aromatase are expressed in many other cell types throughout the TME. These cells are estrogen sensitive and can directly or indirectly affect tumor cells differently in response to estrogen stimulation. The cells Figure 1 . Estrogen can promote pro-tumor or antitumor tumor microenvironment (TME) depending on the cell type and the dominate estrogen receptor (ER) stimulated. A, Estrogen signaling on tumor cells can be mediated by ERa or ERb. These receptors were shown to have opposing functions mediating cancer cell survival and proliferation. Although era signaling can promote proliferation through upregulation of c-myc and cyclin D1, ERb inhibits cyclin E and cell cycle progression. The ERa was shown to also inhibit apoptosis of cancer cells through the upregulation of antiapoptotic genes like Bcl-1 and Bcl-xl, but ERb signaling can induce apoptosis through p53-related mechanism. B, Estrogen signaling can not only affect tumor cells but many other cells present on the TME which express ERs and are estrogen sensitive. It was shown that in liver cancer, melanoma, and endometrial cancer estrogen signaling promotes the antitumor immune response by either inhibiting cytokine production that promotes chronic inflammation and suppressive immune cells recruitment (interleukin [IL]-8 and IL-6), or by inhibiting macrophage differentiation into tumor-associated macrophages (TAMs). C, In other cancers like ovarian, lung, and specially breast cancer, estrogen signaling promotes pro-tumor functions in the TME immune and stromal cells. Estrogen signaling promotes pro-tumor TME by shifting the balance in favor of Th2 responses, inducing immunosuppressive cell function (Tregs, myeloid-derived suppressor cell [MDSCs]), and promoting TAM polarization. Stromal cells such as cancer-associated fibroblasts (CAFs) can produce estrogen and increase the TME estrogen concentration affecting estrogen-sensitive tumor cells and promoting their growth. Overall, estrogen and ER signaling in the TME is tumorspecific, cell type-specific, and dependent on the main ER signaling. Therefore, estrogen cannot be generally considered as an oncogene or a tumor suppressor.
in the TME include stromal cells, innate immune cells, and adaptive immune cells. Each cell type is differentially affected by estrogen (see Figure 1 )
Stroma
Stromal cells are connective tissue cells that support the function of the parenchymal cells of an organ or a tumor. Some common stromal cells include fibroblasts and periocytes. The interaction between stromal cells and tumor cells has been studied and were reported to play major roles in cancer growth and progression. 38, 39 Stromal cells were shown to express aromatase, the enzyme that converts androstenedione into estrogen, and also express both ERs, so they are affected by estrogen signaling in much the same way as cancer cells. Stromal cells in human breast cancer, melanoma, NSCLC, and endometrial cancer were found to express ERs and undergo ERa and ERb signaling upon estrogen stimulation. It was shown that in ovariectomized (OVX) mice challenged with ER À tumor cell lines, estrogen treatment increased tumor growth via interactions with stromal ERa. 40 Estrogen-induced tumor growth was at least partially due to increased tumor angiogenesis through ERa signaling in stromal cells. 40 ERa positively transcriptionally regulated angiopoietin-1 receptor (Tie2) which is a transmembrane tyrosine-protein kinase receptor for angiopoietin 1, 2, and 4 (ANGPT1/2/4) for which downstream signaling results in increased angiogenesis. 41 Tie2-deficient stromal cells were not able to promote ER À tumor cell growth. Tumor growth was even more accentuated in immune-deficient mice, meaning that the antitumor immune response also had an important role controlling the tumor. 40 Aromatase expression in stromal cells is associated with advanced disease and worst prognosis in endometrial and breast tumors. 42, 43 This means that stromal cells can not only synthesize estrogen and undergo estrogen paracrine signaling which can increase angiogenesis, but they also increase the estrogen concentration in the TME which affects estrogen-sensitive tumor cells.
Cancer-associated fibroblasts (CAFs) are among the most prevalent stromal cell type in the TME. The CAFs can promote pathways involved in tumor cell survival, invasion, and metastasis acting as a paracrine source of soluble chemokines, and growth factors. 44 In human breast, prostate, endometrial, and ovarian tumors, CAFs were shown to be estrogen sensitive, since they express both ERs, allowing them to respond to estrogen and aromatase which means they can also synthesize estrogen. 45 One study compared ERa expression in CAFs and healthy fibroblasts in tumors versus healthy breast tissue. Even if CAFs and healthy fibroblasts showed similar ERa expression, the downstream gene liver receptor homolog-1 was highly upregulated in CAFs only. 46 LHR-1 is an estrogen-responsive gene, and it is a transcriptional regulator of aromatase, indicating an estrogen/ER-positive feedback loop only in CAFs. 47 Endometrial CAFs express both ERa and ERb and can promote tumor cell proliferation through the phosphoinositol 3 kinase and the mitogen-activated protein kinase pathways. 48, 49 In prostate cancer, the role of ER-expressing CAFs is controversial. One study described CAF ERa and ERb expression as a marker of clinically advanced disease. 50 On the other hand, some studies have shown that estrogen-sensitive CAFs can suppress tumor growth, invasion, and metastasis through reduced IL-6 and C-C motif chemokine ligand 5 expression. 51, 52 Innate Immune Cells
The TAMs together with myeloid-derived suppressor cells (MDSCs) and T regs are considered major tumor-promoting immune cells in the TME. 53 Macrophages are immune cells with a high degree of functional and phenotypic heterogeneity. Macrophages elicit tissue-specific immune responses that depend on the cell polarization caused by exposure to different chemokines, cytokines, and growth factors. Fully polarized classically activated macrophages produce pro-inflammatory factors such as tumor necrosis factor a (TNFa), IL-12, and interferon g (IFNg). 54 On the other hand, alternatively activated macrophages stimulated by IL-14, IL-10, or IL-13 are considered more immune-suppressive, and they can produce tumor-promoting factors such as IL-4, IL-5, IL-6, and IL-10. 54 The TAMs display alternatively activated-like properties, and their presence in the TME is correlated with poor prognosis in many cancers such as ovarian cancer, in which there are TAMs density-dependent associations with 5-year survival rates. 55 Macrophages are especially difficult to characterize, as they are well known to continue to shift their functional phenotype as their environment changes. 56 Because of their extreme functional plasticity, TAMs have been the target of many immunotherapy-based approaches, especially to change their function to the more classically activated phenotype through the use of cytokines such as IL-12. 56 However, even if the effect of SERMs on macrophage function and phenotype remains to be determined, estrogen stimulation does play an important role on macrophage polarization. Some studies claim that estrogen can induce anti-inflammatory macrophage polarization via enhancement of IL-4 responsive genes. 57, 58 Although these studies elegantly showed increased macrophage polarization upon estrogen treatment, they were contradicted by other studies that showed the opposite. In liver cancer, estrogen signaling through ERa and not ERb inhibited TAM polarization and activation via inhibition of the Janus kinase 1 signal transducer and activator of transcription 6 (STAT6) signaling pathway. 37 These contradictory studies are likely due to the nature of the macrophage constantly adapting its phenotype.
The TAMs were observed to express aromatase and both ERs in cancers such as ovarian, breast, and NSCLC. In ovarian cancer, TAMs express both ERa and ERb, and it was observed that premenopausal women have a higher frequency of TAMs than postmenopausal women indicating a role for estrogen signaling. 59 Similar observations were made in endometrial and breast cancers. The TAMs express aromatase and enhance ER þ tumor cell proliferation through increased local estrogen production 60 estrogen and the microenvironment of breast cancer. Estrogen can also increase expression and secretion of vascular endothelial growth factor by TAMs in lung cancer which can further recruit and/or polarize macrophages expressing anti-inflammatory properties to tissues. 61 Taken together, these studies suggest a potential positive feedback mechanism between the estrogen pathway and TAM infiltration in certain cancers. Targeting this interaction may therefore provide therapeutic benefits as recently demonstrated in a lung cancer xenograft model using the phytoestrogen SERM resveratrol. 62 The study showed resveratrol treatment significantly suppressed tumor growth by inhibiting antiinflammatory macrophage polarization of TAMs and decreasing activation of STAT3 signaling which is activated in TAMs. 62 The MDSCs are also tumor-promoting innate immune cells present in the TME. The MDSCs are morphologically and phenotypically similar to neutrophils, macrophages, and monocytes. 63 Similar to TAMs, presence of MDSCs in the TME is correlated with worse disease prognosis. It was not until recently that ER expression and estrogen sensitivity was identified on MDSCs present in ovarian tumors. Svoronos et al found that in OVX mice, there was a better prognosis for ovarian cancerbearing mice compared to wild-type (WT) mice or estrogentreated mice which showed increased tumor progression. 64 Interestingly, the benefit on survival of OVX mice was abrogated when immune-deficient mice were tumor challenged. 64 When the tumors were analyzed, it was observed that estrogen-treated mice had less infiltrating T cells and increased MDSCs in the tumor. 64 In vitro, estrogen increased the MDSCs T-cell suppression ability but this was abrogated when 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole (MPP)-dihydrochloride (selective ERa inhibitor) was used. Most importantly, the estrogen-promoting effects observed in ovarian cancer were eliminated when mice were treated with anti-Gr-1 (MDSC depleting antibody). 64 Overall, these findings indicated that in ovarian cancer, estrogen signaling through ERa can promote tumor formation by inhibition of T-cell antitumor immune responses. Conversely, in a model of mouse melanoma, B16 melanoma, it was found that although tumors grew more rapidly in the female mice compared to male mice, the tumors of the male mice contained a higher frequency of cells with the MDCS phenotype, CD11b
Taken together, these data suggest that the effect of estrogen stimulation on MDSCs may be environment-specific. The MDSCs are considered an immature innate immune cell subset. Estrogen has a clear role in regulation of innate immune cell maturation 66 ; therefore, the signaling pathway activated by estrogen may be manipulated depending upon other stimulation simultaneously encountered in each TME.
Another innate immune cell commonly found in the TME are dendritic cells (DCs). The DCs are professional antigenpresenting cells (APCs), and infiltration of mature, active DCs into the tumor increases immune activation and recruitment of immune effector T cells. Tumor cells have means of suppressing canonical DC function and promoting immunesuppressive DC phenotypes. These immune-suppressant cells are tumor promoting, and they are denominated tumorassociated DCs (TA-DCs). The TA-DCs are very heterogeneous depending on the patient or type of cancer so the relationship between TA-DC frequency in the tumor and clinical outcome is not completely understood. Some populations of TA-DCs can directly inhibit T-cell activation through the expression of immunosuppressant surface ligands programmed cell death ligand 1 and 2 (PD-L1/2), 67 secretion of suppressive cytokines such as IL-10 and TGFb, 68, 69 and expression of suppressive enzymes, arginase, and indoleamine 2,3-dioxygenase (IDO). 70, 71 Some of these immunosuppressant functions are regulated by the transcription factor FOXO3 which can upregulate TGFb, IDO, and arginase. 72 Interestingly, FOXO3 expression and function are affected by sex and ER signaling, and FOXO3 can bind to the ERa promoter indicating a feedback loop between them. 65, 72 Estrogen stimulation rapidly induced FOXO3 in TA-DC, but most interestingly FOXO3 was more rapidly degraded than in untreated TA-DCs. 65 It was found that even if FOXO3 was upregulated in TA-DCs from both males and females in several cancers, removing FOXO3 has more of a tumor-protective effect on females than males to the point of females being completely protected from liver cancer. 65 Overall, it could be concluded that estrogen stimulation could reduce the immunosuppressive functions of TA-DCs through FOXO3 degradation, increasing the T-cell antitumor immune response.
Adaptive Immunity
The lymphocyte composition of the TME vastly varies based on the cancer type, and the immune infiltrates can exhibit opposing properties promoting or inhibiting tumor progression depending on the environment and tumor cells. 45 Cytotoxic CD8 þ T cells are well known to be the main players on the antitumor immune response and can kill tumor cells directly through secretion of perforin and Granzyme B.
73 CD4 þ T-cell role in the TME is more complex, since CD4 þ T cells are subdivided in different subsets with nonreciprocal functions. CD4 þ T-cell polarization was shown to be an important mediator of antitumor immune responses versus immune tolerance. T helper 1 (Th1) CD4 þ Tcell responses are known to mediate tumor killing and suppression though secretion of antitumor cytokines such as IFNg and TNFa. 73 On the other hand, Th2 CD4 þ T-cell responses which induce IL-4 production are considered tumor promoting. Th17 CD4 þ T-cell responses are considered tumor suppressive, and T regs are well known to promote tumorigenicity and immune tolerance through immune suppression. 73 Both CD8 þ and CD4 þ T cells express ERa and ERb and are estrogen sensitive. Many studies describe the effect of estrogen and ER signaling on CD8 þ and CD4 þ T cells as described in other sections of this chapter. In ER À breast cancers, increased infiltrating T cells and B cells were found infiltrating the tumor compared to ER þ breast tumors. 74 A negative correlation between ER activity and immune infiltration of T cells and B cells was found, confirming that T-cell infiltration in ER À tumors significantly correlates with improved overall survival. 74, 75 Additionally when ER þ breast cancer cells were treated with the aromatase inhibitor AI letrozole, then an increased infiltration of T and B cells was observed following treatment initiation. 74 Overall, estrogen inhibits lymphocyte infiltration of tumors in ER þ breast cancer. Cytotoxic lymphocytes (CTLs) and natural killer cells (NKs) are adaptive immune cells critical for their ability to target and destroy tumor cells. The tumor has many ways to suppress antitumor immune responses and evade destruction by CTLs and NK cells. One study described a mechanism by which ERa þ tumor cells from liver and breast cancer (MCF-7 cell line) were treated with estrogen, where the tumor upregulated the granzyme B inhibitor proteinase inhibitor-9 (PI-9). 76 Granzyme B is a cytolytic molecule necessary for tumor cell killing, a primary means of tumor cell destruction by CTL and NK. The increased production of PI-9 therefore means that estrogen was enhancing immunosuppression via inhibition of CTL and NK cytotoxicity. This study was performed treating the tumor cells and did not describe the direct effects of estrogen signaling on tumor infiltrating CTL or NK. Further studies would be required to determine whether additional direct effects of estrogen would also impact CTL and NK tumor targeting.
T regs are immunosuppressive CD4 þ tumor-infiltrating lymphocytes that are recruited to the TME by the tumor cells via chemokines such as CCL22. 77 T regs express FoxP3 and many immune suppressive markers including IL-10, lymphocyteactivation gene 3 (LAG-3), CTLA-4, and glucocorticoidinduced TNFR-related protein and they are well known to inhibit CTL function. 78 T regs express ERa and they are estrogen sensitive. However, once again the role of estrogen regulating T reg function and phenotype is contradictory. One study showed that treating immunocompetent OVX mice with physiological doses of estrogen-enhanced CD4 þ CD25 þ T reg expansion and upregulated Foxp3 expression in multiple tissues. 79 Physiological estrogen-treated CD4 þ
CD25
þ T cells exhibited increased suppression of T-cell proliferation in mixed lymphocyte reactions in vivo and in vitro. 79 Although elegantly shown that physiological concentrations of estrogen can induce T reg phenotype, the TME estrogen concentrations are commonly dysregulated and could be much higher than physiological. In a study demonstrating the effects of sex and estrogen signaling on anti-PD-1 immunotherapy, it was observed that estrogen treatment could reduce T reg suppressive function on effector T cells, and this was reversed by the use of an ERa-selective inhibitor. 80 Due to this effect, females treated with immune checkpoint blockade therapy benefited from it more than their male counterparts. 80 
Summary
The effect of estrogen treatment and ER signaling is very cell-specific. Immune cells infiltrating TMEs express both the ERa and the ERb. Estrogen favors pro-inflammatory, antitumor immune cell functions and inhibits immune suppressive cells types including T reg , MDSC, and TAMs.
Section 3: The Effect of Estrogen on Antitumor Immunity
Immune-based therapies for cancer have taken the spotlight in recent years for successful treatment of many types of cancer. These immune-based therapies include checkpoint blockade therapies such as anti-PD-1 and anti-CTLA-4 designed to prevent T cells from being turned-off by ligand-expressing tumor cells or APCs. 81, 82 Therapies also include adoptive transfer of genetically modified T cells or chimeric antigen receptor T cells. 83, 84 Although these treatments have achieved impressive levels of success, there are still many hurdles yet to overcome. One of those hurdles is to understand the mechanisms at play that allow one patient to achieve cancer remission while a second patient have no relief in tumor burden at all. We hypothesize that the effect of estrogen on T cells, both endogenous and those adoptively transferred may make a difference. This section will review the effects of estrogen on T-cell development, function, and ability to generate an antitumor immune response.
Estrogen Regulation of CD8
þ T-Cell Development. In the female body, levels of circulating serum estrogen cycle throughout life. Estrogen (E2) concentrations are variable during the menstrual cycle (ranging from 0.2 to 1 nmol/L per mL, ie, 1 nmol/ L/mL), high during pregnancy (ranging from 1 nmol/L in the first trimester to up to 20 nmol/L in third), and low after menopause (<0.1 nmol/L). 42, 85 In males, the concentrations of E2 remain low through life at around 0.1 nmol/L. 42 These variable concentrations of E2 can affect the maturation, differentiation, and function of T cells which express estrogen receptors ERa and ERb. The ERa is highly expressed on all immune cells, but CD8 þ and CD4 þ T cells express both estrogen receptors, ERa and ERb. Circulating female CD4 þ T cells express higher levels of ERa compared to ERb, and the receptors are significantly more numerous than on CD8 þ T cells. 86, 87 Circulating CD8 þ T cells express higher levels of ERa than ERb although there is a lower concentration of both than in the case with CD4 þ T cells. Female CD8 þ T-cell ER expression remains constant through life (pre-and postmenopause), and it is equivalent to that of male CD8 þ T cells. 86 The ERa plays a very important role on CD8 þ T-cell development and differentiation. For example, ERa knock out (ERKO) mice had significantly smaller thymi than WT mice. 88 Staples et al showed that the reduced size of the thymi in ERKO mice was due to the lack of ERa in the thymic stromal cells and not in the hematopoietic compartments as shown by bone marrow chimera experiments. 88 Erlandsson et al showed that ERKO mice have smaller thymi and smaller spleens compared to WT. 89 The thymi also had increased numbers of CD4 þ CD8 þ immature thymocytes compared to single positive thymocytes (CD4 þ or CD8 þ ). 89 Also, female OVX mice showed a similar degree of thymic and spleen atrophy but no change in CD4/CD8 frequencies compared to WT females. 89 On the other hand, treating OVX animals with exogenous estrogen resulted in thymic atrophy and increased frequencies of single positive CD4 þ and CD8 þ thymocytes. 90, 91 Overall, it can be concluded that estrogen signaling through ERa is necessary for full development of the thymus as well as CD4 and CD8 single positive mature T-cell development. Very little is known about the effect of estrogen signaling on CD8 þ T-cell function since most studies were performed on CD4 þ T-cell subsets. What was extensively shown by many studies is that estrogen signaling can modulate IFNg expression and secretion in both human and mouse T cells.
92 CD8 þ T cells are strongly associated with cytolytic activity, either by directly killing antigen (Ag)-expressing targets by secretion of cytolytic granules like perforin and granzyme B or by expressing apoptotic molecules like FasL. [93] [94] [95] Additionally, Ag-activated CD8 þ T cells can also secrete IFNg which is a proinflammatory cytokine that allows CD8 þ T cells to act systemically, whereas the cytolytic granules and FasL can connect with target cells for killing. 95 The IFNg promotes CD8 þ T-cell activation and proliferation and is an antiviral cytokine that recruits other adaptive and innate immune cells to the site of infection. 96 Interferon g also has an important role in establishing antitumor immunity, since it is necessary for T-cell infiltration into the TME, sustained T-cell activation and for the direct killing of tumor cells.
97,98

Estrogen Effect on Cytokine Production
Estrogen can modulate IFNg secretion by enhancing IFNg gene expression in CD8 þ T cells. This happens through direct interaction of ERa with an estrogen response element in the promoter of the Ifng gene. 92 The ERa-deficient mice had decreased numbers of IFNg producing cells in their lymph nodes. 99 This was also shown in human antigen-specific T cells which upregulated both their expression and secretion of IFNg upon Ag-stimulation when they were treated with exogenous estrogen. 100 Also, blocking ERb with the selective inhibitor 2-Phenyl-3-(4-hydroxyphenyl)-5,7-bis(trifluoromethyl)-pyrazolo[1,5-a]pyrimidine,4-[2-Phenyl-5,7-bis(trifluoromethyl)-pyrazolo[1,5-a]-pyrimidin-3-yl]phenol upregulated IFNg expression even higher in the presence of estrogen meaning that ERa and ERb could be competing for estrogen ligand binding and only ERa has activating gene regulatory properties for IFNg. 100 When the selective ERa inhibitor MPPdihydrochloride was used in combination with estrogen treatment, no changes in IFNg expression were observed, reaffirming that ERa is a specific transcriptional regulator of IFNg in CD8 þ T cells. 100 Navarro and Watkins recently showed that estrogen can upregulate secretion of granzyme B in female human Agspecific T cells in response to Ag stimulation. Such effect was not observed on male CD8 þ T cells which already showed a higher granzyme B secretion than was the case in estrogentreated female T cells. This was due to male donor T-cell populations having a higher ratio of CD8:CD4 T cells compared to female donors. 100 This supported the conclusion that estrogen modulates differentiation of human single positive CD4/CD8 T cells, which is the reason that males and females show different ratios of T-cell subsets worldwide. 101 Furthermore, the same study also reported that estrogen treatment increased TNFa and IL-4 secretion on CD8 þ T cells of both males and females. 100 The positive estrogen effect on IL-4 expression was shown to be completely dependent on ERa because once T cells were treated with estrogen in combination with MPP-dihydrochloride, which is a complete blockade of the ERa, IL-4 secretion was lowered to the level of unstimulated T cells in both males and females. 100 On the other hand, selectively blocking ERb had no effect on IL-4 expression, but it did have a positive effect on TNFa expression suggesting ERa/ERb competition for ligand binding, similar to the case of IFNg. Overall, estrogen increased CD8 þ T-cell IFNg and granzyme B production in female Agspecific T cells and increased TNFa and IL-4 production in both male and female Ag-specific T cells. Male T cells already produced higher IFNg and granzyme B due to a higher overall CD8:CD4 T-cell ratio. 100 Estrogen Effect on CD8 þ T-Cell Polyfunctionality
Polyfunctionality of CD8 þ T cells is critical in generating superior immune responses against bacterial and viral infections, and more importantly against cancer. It was shown that at baseline estrogen treatment, female Ag-specific T cells are overall more polyfunctional than male T cells in response to Ag-stimulation. When treated with physiological concentrations of estrogen (0.5 nmol/L), polyfunctionality of both male and female T cells increased, suggesting that estrogen signaling not only affects single cytokine production but overall T cell polyfunctionality. 100 When treated with superphysiological estrogen (50 nmol/L), polyfunctionality of both male and female T cells slightly decreased even if the female T cells still showed greater polyfunctionality than the male cells. These data demonstrated that the effect of estrogen on T-cell polyfunctionality is dose dependent and that physiological estrogen levels seems to have the more optimal effect compared to superphysiologic concentrations. Even if the experiments analyzing 1 cytokine or marker at the time showed a dosedependent response upon estrogen treatment, polyfunctionality did not follow this trend which could be due to an increase in single positive cells (expressing only one marker) which explains the loss of polyfunctionality at superphysiological estrogen levels.
Summary
Both mouse and human CD8 þ T cells express functional ERa and ERb. Estrogen signaling through ERa is necessary for full differentiation of CD8 þ T cells. 88, 89 ERa directly increases production of granzyme B, TNFa, IL-4, and IFNg, in CD8 þ T cells, albeit differently in males compared to females.
Estrogen differentially effects polyfunctionality of male and female human T cells and results in increased polyfunctionality in female CD8 þ T cells. The effects of estrogen of CD8 þ T cells are dependent on which receptor is mainly signaling, availability of the estrogen ligand, and concentration of the ligand.
Conclusions
Estrogen has long been known to play a role in the development of immune cell populations, going from immature to mature phenotypes. However, more recent studies demonstrate clearly that the outcome of immune responses are highly dependent upon the concentration of estrogen, the duration of the stimulation, and other factors present in combination with the hormone. Estrogen signaling manipulates T cell including the modulating T cells that would otherwise be beneficial in fighting cancer but become exhausted or lose polyfunctionality. A better understanding of all the ways estrogen regulates T-cell function is on the horizon and may be a key determinant to enhancing immune-based therapies for disease.
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